Cartesian Therapeutics, Inc. (RNAC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Carsten Brunn Ph.D. | President, CEO & Director | 4.67M | -- | 1972 |
| Mr. Blaine T. Davis | Chief Financial Officer | 2.49M | -- | 1975 |
| Dr. Metin Kurtoglu M.D., Ph.D. | Chief Technology Officer | 398.28k | -- | 1979 |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer | 296.85k | -- | 1982 |
| Mr. Matthew Bartholomae J.D. | General Counsel & Secretary | -- | -- | -- |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer | -- | -- | 1984 |
| Dr. Emily English Ph.D. | SVP & Head of Manufacturing | -- | -- | 1980 |
| Mr. Yi Zhang Ph.D. | Senior Director of Technology | -- | -- | -- |
Cartesian Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 37
Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Corporate Governance
Upcoming Events
August 15, 2024 at 12:30 PM UTC - August 19, 2024 at 12:30 PM UTC
Cartesian Therapeutics, Inc. Earnings Date
Recent Events
May 20, 2024 at 7:00 PM UTC
Cartesian Therapeutics Inc at HC Wainwright BioConnect Investor Conference
March 27, 2024 at 1:00 PM UTC
Cartesian Therapeutics Inc Extraordinary Shareholders Meeting
March 26, 2024 at 3:00 PM UTC
Cartesian Therapeutics Inc at HC Wainwright Cell Therapy Conference (Virtual)